Health Kick Podcast: ATH434 and the mission to treat multiple system atrophy

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim speaks with Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler, who sheds light on a little-known but devastating neurological condition, multiple system atrophy (MSA).

MSA may not have the public awareness of Parkinson’s or ALS, but it’s every bit as serious, and Alterity is aiming to change that.

With no approved treatments currently available, MSA represents a major unmet clinical need.

Alterity’s lead candidate, ATH434, is designed to address a unique biological mechanism involving iron imbalance in the brain.

Tune in to hear how ATH434 is showing promise in slowing disease progression, the science behind iron maldistribution in neurodegenerative disease, and how Dr Stamler’s decades of FDA drug development experience is helping drive this program forward.

This podcast was developed in collaboration with Alterity Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.